Navigation Links
Clinical course of subepithelial lesions

Although several studies pertaining to the natural history of subepithelial tumors have been published, they have been limited by small sample size and relatively short follow-up. The natural history of subepithelial lesions has not been clearly elucidated, and the appropriate management strategy for small subepithelial tumors is still controversial.

A research article to be published on January 28, 2010 in the World Journal of Gastroenterology addresses this question. The research team from South Korea reviewed the medical records of 104 159 patients who underwent upper gastrointestinal endoscopy at the Center for Health Promotion of Samsung Medical Center between 1996 and 2003.

Their results showed that of the 252 lesions, 244 (96.8%) were unchanged. And endoscopic surveillance can be an appropriate strategy for lesions < 1 cm. Further prospective, multicenter studies with long-term follow-up would help to validate these surveillance programs.


Contact: Ye-Ru Wang
World Journal of Gastroenterology

Page: 1

Related medicine news :

1. Pluromed Announces Completion of Enrollment in LeGoo&#8482; Cardiac Bypass Clinical Trial
2. NHLBI funds preclinical tests on devices for infants and children with congenital heart defects
3. Medpedia Launches New Clinical Trial Platform
4. Banner Health Systems Adopts Quantros Regulatory Reporting Management (RRM) to Manage Clinical Quality and Performance Data and Support Improvements in Quality of Care
5. Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information
6. European Cancer Organization supports a revision of the EU Clinical Trials Directive
7. Roche and Catalyst Resources Team to Explore RIA Healthcare Collaboration Solutions for Enhanced Clinical Diagnosis and Education
8. Sunquest Introduces the Integrated Clinical Environment Physician Portal to US Marketplace
9. HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.
10. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
11. ePRO on Netbooks (NetPRO) - The BEST ePRO Solution for Clinical Trials in 15 Years
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: